124
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer

, , , , , & show all
Pages 63-69 | Received 09 Jan 1995, Accepted 20 Jun 1995, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Farah Diba Begum, Estrid Høgdall, Ib Jarle Christensen, Susanne Krüger Kjaer, Jan Blaakaer, Lise Christensen & Claus Høgdall. (2010) Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstetricia et Gynecologica Scandinavica 89:2, pages 190-198.
Read now

Articles from other publishers (12)

Brian M. Nolen & Anna E. Lokshin. 2014. Advances in Diagnosis and Management of Ovarian Cancer. Advances in Diagnosis and Management of Ovarian Cancer 33 58 .
Anna E. Lokshin. (2012) The Quest for Ovarian Cancer Screening Biomarkers. International Journal of Gynecological Cancer 22, pages S35-S40.
Crossref
B. GRONLUND, H. DEHN, C.K. HOGdall, S.A. ENGELHOLM, M. JORGENSEN, B. NORGAARD-PEDERSEN & E.V.S. HOGDALL. (2005) Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. International Journal of Gynecological Cancer 15:5, pages 836-843.
Crossref
N. R. Caterer, J. H. Graversen, C. Jacobsen, S. K. Moestrup, B. W. Sigurskjold, M. Etzerodt & H.C. Thøgersen. (2002) Specificity Determinants in the Interaction of Apolipoprotein(a) Kringles with Tetranectin and LDL. Biological Chemistry 383:11, pages 1743-1750.
Crossref
Claus K. Høgdall, Ib J. Christensen, Ross W. Stephens, Steen Sørensen, Bent NØRgaard‐Pedersen & Hans J. Nielsen. (2003) Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI‐1 and serum CEA. APMIS 110:9, pages 630-638.
Crossref
M. Sharon Stack & David A. FishmanRobert C. BastJr.Jr., Nicole Urban, Viji Shridhar, David Smith, Zhen Zhang, Steven Skates, Karen Lu, Jinsong Liu, David Fishman & Gordon Mills. 2002. Ovarian Cancer. Ovarian Cancer 61 97 .
JM Riedinger, S Basiletti, S Lizard, F Mayer, P Fargeot, J Cuisenier & B Coudert. (2001) Évaluation clinique du cancer associated serum antigen (CASA) comme marqueur tumoral des cancers ovariens : comparaison avec le CA 125. Immuno-analyse & Biologie Spécialisée 16:3, pages 172-182.
Crossref
Xiaohong Deng, Estrid V.S. Høgdall, Claus K. Høgdall, Bent Nørgaard-Pedersen, Morten Jørgensen, Henrik Nielsen & Svend A.A. Engelholm. (2000) The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer. Gynecologic Oncology 79:3, pages 416-419.
Crossref
Estrid V.S. Høgdall, Claus K. Høgdall, Solveig Tingulstad, Bjørn Hagen, Kjell Nustad, Feng‐Ji Xu, Robert C. Bast & Ian J. Jacobs. (2000) Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer 89:6, pages 519-523.
Crossref
Elli F Kamper, Anastasios D PapahilisS, Maria K Angelopoulou, Ludmila T Kopeikina, Marina P Siakantaris, Gerassimos A Pangalis & John C Stavrudis. (1999) Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia. Clinical Biochemistry 32:8, pages 639-645.
Crossref
Peter J. Neame, Hazel Tapp & David R. Grimm. (1999) The cartilage-derived, C-type lectin (CLECSF1): structure of the gene and chromosomal location. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1446:3, pages 193-202.
Crossref
J.M. Riedinger, S Lizard, B Coudert & I Barillot. (1999) Intérêt clinique du calcul des pentes de variation du CA 125 pour la surveillance biologique des tumeurs épithéliales ovariennes. Immuno-analyse & Biologie Spécialisée 14:4, pages 244-250.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.